These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 16235052)

  • 1. Human T lymphocyte responses against lung cancer induced by recombinant truncated mouse EGFR.
    Hu B; Wei YQ; Tian L; Zhao X; Lu Y; Wu Y; Yao B; Zhang XW
    Cancer Immunol Immunother; 2006 Apr; 55(4):386-93. PubMed ID: 16235052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor.
    Lu Y; Wei YQ; Tian L; Zhao X; Yang L; Hu B; Kan B; Wen YJ; Liu F; Deng HX; Li J; Mao YQ; Lei S; Huang MJ; Peng F; Jiang Y; Zhou H; Zhou LQ; Luo F
    J Immunol; 2003 Mar; 170(6):3162-70. PubMed ID: 12626574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active antitumor immunity elicited by vaccine based on recombinant form of epidermal growth factor receptor.
    Hu B; Wei Y; Tian L; Zhao X; Lu Y; Wu Y; Yao B; Liu J; Niu T; Wen Y; He Q; Su J; Huang M; Lou Y; Luo Y; Kan B
    J Immunother; 2005; 28(3):236-44. PubMed ID: 15838380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral immunity responses against EGFR-positive tumor cells induced by xenogeneic EGFR expressed in the yeast Pichia pastoris.
    Fang F; Chen P; Chen XC; Li J; Wen YJ; Wei YQ
    Int J Mol Med; 2009 Feb; 23(2):181-8. PubMed ID: 19148541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2.
    Liu JY; Wei YQ; Yang L; Zhao X; Tian L; Hou JM; Niu T; Liu F; Jiang Y; Hu B; Wu Y; Su JM; Lou YY; He QM; Wen YJ; Yang JL; Kan B; Mao YQ; Luo F; Peng F
    Blood; 2003 Sep; 102(5):1815-23. PubMed ID: 12750177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy.
    Kumai T; Matsuda Y; Oikawa K; Aoki N; Kimura S; Harabuchi Y; Celis E; Kobayashi H
    Br J Cancer; 2013 Oct; 109(8):2155-66. PubMed ID: 24045666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non-small cell lung cancer.
    Akazawa Y; Saito Y; Yoshikawa T; Saito K; Nosaka K; Shimomura M; Mizuno S; Nakamoto Y; Nakatsura T
    Cancer Sci; 2020 Aug; 111(8):2736-2746. PubMed ID: 32391625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy.
    Fong L; Brockstedt D; Benike C; Breen JK; Strang G; Ruegg CL; Engleman EG
    J Immunol; 2001 Dec; 167(12):7150-6. PubMed ID: 11739538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active immunotherapy of tumors with a recombinant xenogeneic endoglin as a model antigen.
    Tan GH; Wei YQ; Tian L; Zhao X; Yang L; Li J; He QM; Wu Y; Wen YJ; Yi T; Ding ZY; Kan B; Mao YQ; Deng HX; Li HL; Zhou CH; Fu CH; Xiao F; Zhang XW
    Eur J Immunol; 2004 Jul; 34(7):2012-21. PubMed ID: 15214049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor peptide vaccination induces cross-reactive immunity to human EGFR, HER2, and HER3.
    Doyle HA; Koski RA; Bonafé N; Bruck RA; Tagliatela SM; Gee RJ; Mamula MJ
    Cancer Immunol Immunother; 2018 Oct; 67(10):1559-1569. PubMed ID: 30056598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo.
    Foy KC; Wygle RM; Miller MJ; Overholser JP; Bekaii-Saab T; Kaumaya PT
    J Immunol; 2013 Jul; 191(1):217-27. PubMed ID: 23698748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen.
    Gold JS; Ferrone CR; Guevara-Patiño JA; Hawkins WG; Dyall R; Engelhorn ME; Wolchok JD; Lewis JJ; Houghton AN
    J Immunol; 2003 May; 170(10):5188-94. PubMed ID: 12734366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction of a Recombinant Phage-vaccine Capable of Reducing the Growth Rate of an Established LL2 Tumor Model.
    Asadi-Ghalehni M; Rasaee MJ; Namvar Asl N; Khosravani M; Rajabibazl M; Khalili S; Modjtahedi H; Sadroddiny E
    Iran J Allergy Asthma Immunol; 2018 Jun; 17(3):240-249. PubMed ID: 29908541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice.
    Manjili MH; Wang XY; Chen X; Martin T; Repasky EA; Henderson R; Subjeck JR
    J Immunol; 2003 Oct; 171(8):4054-61. PubMed ID: 14530326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cell targeting of survivin protein in a xenogeneic form elicits strong CD4+ T cell immunity to mouse survivin.
    Charalambous A; Oks M; Nchinda G; Yamazaki S; Steinman RM
    J Immunol; 2006 Dec; 177(12):8410-21. PubMed ID: 17142738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variable epitope library carrying heavily mutated survivin-derived CTL epitope variants as a new class of efficient vaccine immunogen tested in a mouse model of breast cancer.
    NoeDominguez-Romero A; Zamora-Alvarado R; Servín-Blanco R; Pérez-Hernández EG; Castrillon-Rivera LE; Munguia ME; Acero G; Govezensky T; Gevorkian G; Manoutcharian K
    Hum Vaccin Immunother; 2014; 10(11):3201-13. PubMed ID: 25483665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutation.
    Yamada T; Azuma K; Muta E; Kim J; Sugawara S; Zhang GL; Matsueda S; Kasama-Kawaguchi Y; Yamashita Y; Yamashita T; Nishio K; Itoh K; Hoshino T; Sasada T
    PLoS One; 2013; 8(11):e78389. PubMed ID: 24223798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MHC II lung cancer vaccines prime and boost tumor-specific CD4+ T cells that cross-react with multiple histologic subtypes of nonsmall cell lung cancer cells.
    Srivastava MK; Bosch JJ; Wilson AL; Edelman MJ; Ostrand-Rosenberg S
    Int J Cancer; 2010 Dec; 127(11):2612-21. PubMed ID: 20473949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Immunogenicity and Anti-Tumor Efficacy of a Rationally Designed EGFR Vaccine.
    Cheng C; Deng L; Li R
    Cell Physiol Biochem; 2018; 46(1):46-56. PubMed ID: 29566364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A plasmid DNA vaccine encoding the extracellular domain of porcine endoglin induces anti-tumour immune response against self-endoglin-related angiogenesis in two liver cancer models.
    Jiao JG; Li YN; Wang H; Liu Q; Cao JX; Bai RZ; Huang FY
    Dig Liver Dis; 2006 Aug; 38(8):578-87. PubMed ID: 16777500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.